RVTYHIGH SIGNALFINANCIAL10-K

RVTY underwent a transformational expansion with revenue surging 365% to $3.3B while simultaneously executing massive share buybacks totaling $821M despite declining net income.

The dramatic revenue and gross profit increases suggest a major acquisition or business transformation that fundamentally changed RVTY's scale and operations. However, the combination of declining net income amid massive revenue growth, coupled with aggressive share buybacks exceeding $800M, raises questions about integration costs, operational efficiency, and capital allocation priorities during this expansion phase.

Comparing 2026-02-24 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

RVTY experienced explosive growth with revenue jumping 365% to $3.3B and gross profit surging 389% to $2.0B, indicating a transformational business expansion likely through acquisition. However, net income declined 11% to $241M despite the revenue surge, suggesting significant integration or operational costs, while the company aggressively repurchased $821M in shares and reduced total debt by 11% to $3.9B. The overall picture shows a company in major transition, dramatically expanding its revenue base while managing integration challenges and returning substantial capital to shareholders, though the sustainability of margins and integration success remain key investor concerns.

FINANCIAL STATEMENT CHANGES
Gross Profit
P&L
+388.8%
$407.0M$2.0B

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+365.3%
$711.8M$3.3B

Strong top-line growth of 365.3% — accelerating demand or successful expansion into new markets.

Share Buybacks
Cash Flow
+122.1%
$369.6M$820.8M

Share repurchases increased 122.1% — management returning capital, signals confidence in intrinsic value.

Current Liabilities
Balance Sheet
+103.8%
$653.1M$1.3B

Current liabilities surged 103.8% — significant near-term obligations; verify ability to meet short-term debt.

Interest Expense
P&L
-21.9%
$63.6M$49.7M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Cash & Equivalents
Balance Sheet
-20.9%
$1.2B$919.9M

Cash decreased 20.9% — monitor burn rate and upcoming capital needs.

Accounts Receivable
Balance Sheet
+17.8%
$632.4M$744.7M

Receivables grew 17.8% — monitor days sales outstanding for collection efficiency.

Total Debt
Balance Sheet
-11.3%
$4.4B$3.9B

Debt reduced 11.3% — deleveraging strengthens balance sheet and reduces financial risk.

Net Income
P&L
-10.8%
$270.4M$241.2M

Net income declined 10.8% — review whether driven by operations, interest costs, or non-recurring items.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-25
ADDED
As of February 20, 2026, there were outstanding 111,799,374 shares of common stock, $1 par value per share.
DOCUMENTS INCORPORA TED BY REFERENCE Portions of Revvity, Inc.
As of December 28, 2025, we employed approximately 11,000 employees.
BioLegend best-in-class antibodies, recombinant proteins, and related reagents, which are used across multiple applications and research areas, including flow cytometry, microscopy, proteogenomics, tissue, cell and protein analysis, cancer research, immunology, cell and gene therapy, stem cell therapy and neuroscience.
TotalSeq reagents offer individual antibodies as well as hashtags for sample pooling and large cocktails for the analysis of hundreds of protein markers.
+7 more — sign up free →
REMOVED
As of February 21, 2025, there were outstanding 120,187,286 shares of common stock, $1 par value per share.
As of December 29, 2024, we employed approximately 11,000 employees.
BioLegend best-in-class antibodies, recombinant proteins, and related reagents are used across multiple applications and research areas, including proteogenomics, tissue, cell and protein analysis, cancer research, immunology, cell and gene therapy, stem cell therapy and neuroscience.
BioLegend s MojoSort for cell separation that complements our fluorophore-antibody conjugates, used for FACS (Fluorescence-activated Cell Sorting), thus covering most cell separation and cell sorting technologies and applications.
BioLegend s catalog of more than 33,000 SKUs, incorporating antibodies and a large collection of antibody conjugates and modifications as well as recombinant proteins, immunoassays, and other supportive reagents and solutions for cell and molecular analysis.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →